(Q36379054)

13 August 2017

1 reference

title

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Winnie Yeo

1

1 reference

13 August 2017

Philip J Johnson

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

43

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

209-220

1 reference

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

13 August 2017

cites work

1 reference

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

21 January 2018

1 reference

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

7 January 2021

Hepatitis B virus infection

1 reference

7 January 2021

Hepatitis B virus infection in Chinese families in Hong Kong.

1 reference

7 January 2021

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

7 January 2021

Hepatitis B infection in patients with lymphomas

1 reference

7 January 2021

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

7 January 2021

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

1 reference

7 January 2021

Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy

1 reference

7 January 2021

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

1 reference

7 January 2021

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan

1 reference

7 January 2021

Frequency of Australia antigen in patients with leukaemia in different countries

1 reference

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

7 January 2021

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

1 reference

7 January 2021

Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

7 January 2021

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

7 January 2021

Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients

1 reference

7 January 2021

An autopsy study of hepatocellular carcinoma in hong Kong

1 reference

7 January 2021

Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC.

1 reference

7 January 2021

Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy

1 reference

7 January 2021

Hepatitis B associated liver failure following bone marrow transplantation

1 reference

7 January 2021

Hepatitis B virus infection and bone marrow transplantation

1 reference

7 January 2021

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

1 reference

7 January 2021

Prevalence of markers of hepatitis B in the adult German population

1 reference

7 January 2021

Molecular diagnosis of viral hepatitis

1 reference

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

7 January 2021

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

7 January 2021

Evaluation of liver fibrosis: a concise review

1 reference

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

7 January 2021

Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases

1 reference

7 January 2021

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD

1 reference

7 January 2021

Clinical and biochemical reactivation of HBV infection in a thalassemic patient after bone marrow transplantation

1 reference

7 January 2021

Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation

1 reference

7 January 2021

Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation

1 reference

7 January 2021

Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation

1 reference

7 January 2021

Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period

1 reference

7 January 2021

Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation

1 reference

7 January 2021

Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation.

1 reference

7 January 2021

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

1 reference

7 January 2021

Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease

1 reference

7 January 2021

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

1 reference

7 January 2021

Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation

1 reference

7 January 2021

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

1 reference

7 January 2021

Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation

1 reference

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

7 January 2021

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

1 reference

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

1 reference

7 January 2021

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

7 January 2021

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

1 reference

7 January 2021

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

7 January 2021

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

1 reference

7 January 2021

Hepatitis B virus reactivation and alemtuzumab therapy

1 reference

7 January 2021

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

1 reference

7 January 2021

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

1 reference

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

7 January 2021

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

1 reference

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

7 January 2021

Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab

1 reference

7 January 2021

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

7 January 2021

Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma

1 reference

7 January 2021

Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy.

1 reference

7 January 2021

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

1 reference

7 January 2021

Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis

1 reference

7 January 2021

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

1 reference

7 January 2021

Biochemical and genetic evidence for the hepatitis B virus replication strategy

1 reference

7 January 2021

Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy.

1 reference

7 January 2021

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

1 reference

7 January 2021

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

1 reference

7 January 2021

Hepatitis B virus DNA contains a glucocorticoid-responsive element

1 reference

7 January 2021

Hepatitis viruses under immunosuppressive agents

1 reference

7 January 2021

The use of corticosteroids in conjunction with antiviral therapy in chronic hepatitis B with ongoing viral replication

1 reference

7 January 2021

Treatment of HBV reactivation after withdrawal of immunosuppression

1 reference

7 January 2021

A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial

1 reference

7 January 2021

Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy

1 reference

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

7 January 2021

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

1 reference

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

7 January 2021

Treatment of chronic hepatitis B: a need for consensus

1 reference

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

7 January 2021

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

1 reference

7 January 2021

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

1 reference

7 January 2021

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

1 reference

7 January 2021

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

1 reference

7 January 2021

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

1 reference

7 January 2021

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

7 January 2021

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

1 reference

7 January 2021

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma

1 reference

7 January 2021

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

1 reference

7 January 2021

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

1 reference

7 January 2021

Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy

1 reference

7 January 2021

Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma

1 reference

7 January 2021

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

1 reference

7 January 2021

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

1 reference

7 January 2021

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

1 reference

7 January 2021

Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine

1 reference

7 January 2021

Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.

1 reference

7 January 2021

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine

1 reference

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

7 January 2021

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin

1 reference

7 January 2021

Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.

1 reference

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

7 January 2021

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

1 reference

7 January 2021

Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection

1 reference

7 January 2021

Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency

1 reference

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

7 January 2021

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

7 January 2021

The maze of treatments for hepatitis B

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21051

1 reference

release_p2dgyucf7naaxo4o7kyafxyfau

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p2dgyucf7naaxo4o7kyafxyfau

24 November 2022

mapped directly with Wikidata item

1 reference